Bionomics Results Presentation Deck

PREVAIL: A Study to Enable Iterative Late-Stage Development LIEBOWITZ SOCIAL ANXIETY SCALE >95: Very severe social phobia i 80-95: Severe social phobia 65-80: Marked social phobia 55-65: Moderate social phobia ↓ 12 Participants I/E Criteria Adults aged 18 to 65 years DSM-5 based diagnosis of SAD No psychotropic meds for 30 days prior to screening I Phase 2 Study Design SCREENING LSAS score ≥ 70 1:1:1 RANDOMIZATION (DOUBLE-BLIND) 225mg ~50 675mg ~50 SINGLE ANXIETY CHALLENGE Placebo ~50 SITES none 20 PRIMARY EFFICACY MEASURE SUBJECTIVE UNITS OF DISTRESS SCALE (SUDS): Visual Analogue Scale (VAS) that measures the self- reported intensity of anxiety and/or distress. 10 30 40 15 US CENTERS N-150 Single Dose Administration mild PREVAIL Study 50 moderate 60 70 severe 80 90 100 very severe Bionomics

View entire presentation